Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease

被引:105
|
作者
Sookoian, Silvia [1 ,3 ,4 ]
Castano, Gustavo O. [3 ,4 ]
Burgueno, Adriana L. [2 ]
Soledad Rosselli, Maria [1 ,2 ]
Fernandez Gianotti, Tomas [2 ]
Mallardi, Pablo [5 ]
San Martino, Julio [5 ]
Jose Pirola, Carlos [2 ]
机构
[1] Univ Buenos Aires, Natl Council Sci & Technol Res CONICET, Inst Med Res A Lanari IDIM, Lab Clin & Mol Hepatol,Mol Genet & Biol Complex D, Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Natl Council Sci & Technol Res CONICET, Inst Med Res A Lanari IDIM, Lab Mol Genet & Biol Metab Syndrome,Mol Genet & B, Buenos Aires, DF, Argentina
[3] Res Council GCBA, Buenos Aires, DF, Argentina
[4] Hosp Abel Zubizarreta, Dept Med & Surg, Buenos Aires, DF, Argentina
[5] Hosp Diego Thompson, Dept Pathol, Buenos Aires, DF, Argentina
关键词
ICAM-1; PAI-1; sCD40L; CD40; Cardiovascular risk; Nonalcoholic steatohepatitis; NASH; NAFLD; Fatty liver; INTERCELLULAR-ADHESION MOLECULE-1; ALCOHOLIC HEPATITIS; METABOLIC SYNDROME; STEATOHEPATITIS; RISK; TISSUE; MEN; SEVERITY; SYSTEM; CELLS;
D O I
10.1016/j.atherosclerosis.2009.10.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We evaluated circulating levels of biomarkers of atherosclerosis (soluble intercellular adhesion molecule: sICAM-1, plasminogen activator inhibitor: PAI-1 and soluble CD40 ligand: sCD40L) in patients with NAFLD proven through biopsy and control subjects, and correlated them with the histological disease severity. We further explored liver protein expression of ICAM-1, CD40 and PAI-1 in patients with different histological forms of NAFLD and control liver biopsies. Patients and methods: We included 215 individuals: 113 patients with NAFLD (simple steatosis n = 45 and NASH n = 68) and 102 control subjects. Circulating levels of the biomarkers were measured by ELISA. Liver expression of ICAM-1, CD40 and PAI-1 was assessed by immunohistochemistry using monoclonal antihuman antibodies. Results: Patients with NAFLD, in comparison with control subjects, showed significantly higher circulating levels of sICAM-1 (605.3 +/- 34.6 ng/ml vs. 356.5 +/- 24.6 ng/ml, p = 5.9 x 10(-6)), PAI-1 (22.8 +/- 1.7 ng/ml vs. 19.0 +/- 2.1 ng/ml, p = 0.0149) and sCD40L (1347.5 +/- 513.7 pg/ml vs. 804.5 +/- 396.1 pg/ml, p = 0.0229), results expressed as mean +/- SE. sICAM-1 was a strong predictor of histological severity of NAFLD, after adjusting for potential confounders. In addition, patients with NAFLD showed significantly higher liver staining scores for ICAM-1 and PAI-1 than control liver biopsies. ICAM-1 immunoreactivity in lobular inflammatory infiltrate showed high scores in NASH patients; a significant correlation was found between both the degree of liver steatosis and the severity of necroinflammatory activity and liver ICAM-1 expression. Conclusions: Our study shows that NAFLD is associated with elevated circulating levels and abnormal liver expression of molecular mediators of atherosclerosis. Additionally, ICAM-1 may be involved in liver damage and inflammation. (C)2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:585 / 591
页数:7
相关论文
共 50 条
  • [1] Nonalcoholic fatty liver disease and atherosclerosis
    Gaudio, Eugenio
    Nobili, Valerio
    Franchitto, Antonio
    Onori, Paolo
    Carpino, Guido
    INTERNAL AND EMERGENCY MEDICINE, 2012, 7 : S297 - S305
  • [2] Nonalcoholic fatty liver disease and atherosclerosis
    Eugenio Gaudio
    Valerio Nobili
    Antonio Franchitto
    Paolo Onori
    Guido Carpino
    Internal and Emergency Medicine, 2012, 7 : 297 - 305
  • [3] Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
    Koo, Seung-Hoi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2013, 19 (03) : 210 - 215
  • [5] Aberrant Hepatic MicroRNA Expression in Nonalcoholic Fatty Liver Disease
    Feng, Yue Ying
    Xu, Xiao Qin
    Ji, Chen Bo
    Shi, Chun Mei
    Guo, Xi Rong
    Fu, Jun Fen
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 34 (06) : 1983 - 1997
  • [6] Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?
    Yusuf Yilmaz
    World Journal of Hepatology, 2012, (12) : 332 - 334
  • [7] Nonalcoholic fatty liver disease and atherosclerosis - Response
    Brea, A
    Ros, E
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (07) : E117 - E118
  • [8] Lipid mediators of liver injury in nonalcoholic fatty liver disease
    Liangpunsakul, Suthat
    Chalasani, Naga
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2019, 316 (01): : G75 - G81
  • [9] Circulating homocysteine in nonalcoholic fatty liver disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    Tsoukas, Michael A.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (02) : 152 - 153
  • [10] Circulating microRNAs in nonalcoholic fatty liver disease
    DiStefano, Johanna K.
    Gerhard, Glenn S.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) : 161 - 163